Association of Nonsteroidal Anti-Inflammatory Drugs, Prostate Specific Antigen and Prostate Volume

Journal of Urology

Volumn 181, Issue 5, 2009, Pages 2064-2070

  Fowke, Jay H ^a   Motley, Saundra S ^a   Smith Jr , Joseph A ^a   Cookson, Michael S ^a   Concepcion, Raoul ^a,b   Chang, Sam S ^a   Byerly, Susan ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Urology Associates   (United States)

Author keywords

anti inflammatory agents; aspirin; non steroidal; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; LEFLUNOMIDE; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PROSTATE SPECIFIC ANTIGEN; SULINDAC;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG USE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RISK REDUCTION; STATISTICAL SIGNIFICANCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIOPSY, NEEDLE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN;

EID: 64049094647     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.01.031     Document Type: Article

References (19)

1. Roehrborn C.G. Definition of at-risk patients: baseline variables. BJU Int 97 suppl. (2006) 7
2. Nickel J.C., Roehrborn C.G., O'Leary M.P., Bostwick D.G., Somerville M.C., and Rittmaster R.S. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE Trial. Eur Urol 54 (2007) 1379
3. Lucia M.S., and Torkko K.C. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 171 (2004) S30
4. Palapattu G.S., Sutcliffe S., Bastian P.J., Platz E.A., De Marzo A.M., Isaacs W.B., et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26 (2005) 1170
5. Wang W., Bergh A., and Damber J.E. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11 (2005) 3250
6. Denkert C., Thoma A., Niesporek S., Weichert W., Koch I., Noske A., et al. Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1. Prostate 67 (2007) 361
7. Shahedi K., Lindstrom S., Zheng S.L., Wiklund F., Adolfsson J., Sun J., et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119 (2006) 668
8. Mahmud S., Franco E., and Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90 (2004) 93
9. Platz E.A., Rohrmann S., Pearson J.D., Corrada M.M., Watson D.J., De Marzo A.M., et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 14 (2005) 390
10. Jacobs E.J., Rodriguez C., Mondul A.M., Connell C.J., Henley S.J., Calle E.E., et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 97 (2005) 975
11. Garcia Rodriguez L.A., and Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 649
12. Smith M.R., Manola J., Kaufman D.S., Oh W.K., Bubley G.J., and Kantoff P.W. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24 (2006) 2723
13. Pruthi R.S., Derksen J.E., Moore D., Carson C.C., Grigson G., Watkins C., et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 12 (2006) 2172
14. Kulkarni G.S., Al-Azab R., Lockwood G., Toi A., Evans A., Trachtenberg J., et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175 (2006) 505
15. Fowke J.H., Signorello L.B., Chang S.S., Matthews C.E., Buchowski M.S., Cookson M.S., et al. Effects of obesity and height on PSA and percent free PSA levels among African-American and Caucasian men. Cancer 107 (2006) 2361
16. Yang C.C., Ku C.Y., Wei S., Shiau C.W., Chen C.S., Pinzone J.J., et al. Peroxisome proliferator-activated receptor γ-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Mol Pharmacol 69 (2006) 1564
17. Conte D., Romanelli F., Fillo S., Guidetti L., Isidori A., Franceschi F., et al. Aspirin inhibits androgen response to chorionic gonadotropin in humans. Am J Physiol Endocrinol Metab 277 (1999) E1032
18. Liu X.H., Kirschenbaum A., Yu K., Yao S., and Levine A.C. Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line. J Biol Chem 280 (2005) 3817
19. Makarov D.V., Trock B.J., Humphreys E.B., Mangold L.A., Walsh P.C., Epstein J.I., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007) 1095